PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Relationship between EGFR Mutations and Pathological Classification and ‚Ä©Specimen of Lung Adenocarcinoma.

Abstract With the development of genetic mutations and targeted drugs, accurate therapy of lung adenocarcinoma attracts much more attention, and more research is focued on epidermal growth factor receptor (EGFR). It is unclear whether the result of EGFR mutation and pathology type is consistent with different specimens. In our study, by comparing the relationship between EGFR mutations and pathological classification of lung adenocarcinoma in surgical resection of specimen and biopsy specimen, to discuss the relationship between EGFR mutations and pathological classification of and the influence of specimen type on EGFR gene detection.
PMID
Related Publications

Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.

Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.

Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types.

Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification.

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Authors

Mayor MeshTerms

Mutation

Keywords
Journal Title zhongguo fei ai za zhi = chinese journal of lung cancer
Publication Year Start




PMID- 28641695
OWN - NLM
STAT- MEDLINE
DA  - 20170623
DCOM- 20170630
LR  - 20170630
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 20
IP  - 6
DP  - 2017 Jun 20
TI  - [Relationship between EGFR Mutations and Pathological Classification and Specimen
      of Lung Adenocarcinoma].
PG  - 382-388
LID - 10.3779/j.issn.1009-3419.2017.06.03 [doi]
AB  - BACKGROUND: With the development of genetic mutations and targeted drugs,
      accurate therapy of lung adenocarcinoma attracts much more attention, and more
      research is focued on epidermal growth factor receptor (EGFR). It is unclear
      whether the result of EGFR mutation and pathology type is consistent with
      different specimens. In our study, by comparing the relationship between EGFR
      mutations and pathological classification of lung adenocarcinoma in surgical
      resection of specimen and biopsy specimen, to discuss the relationship between
      EGFR mutations and pathological classification of and the influence of specimen
      type on EGFR gene detection. METHODS: A total of 163 cases of surgical resection 
      of sample of lung adenocarcinoma (pulmonary resection and pulmonary lobectomy)
      and 173 cases of biopsy specimen [mucosa biopsy, needle biopsy of lung, and
      endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)]
      were performed by gene sequencing method and amplification refractory mutation
      system (ARMS) and the majority of the type was confirmed (lepidic, acinar,
      papillary, micropapillary, solid) according to the classification of lung
      adenocarcinoma in 2015 World Health Organization (WHO). The statistics was used
      in surgical and biopsy sample respectively. RESULTS: The gene mutation of EGFR in
      surgical and biopsy sample of lung adenocarcinoma was 62.58% (102/163) and 65.9% 
      (114/173) respectively, and no significant difference was found (P>0.05). The
      mutation of EGFR in female was predominant both of the two groups (P<0.05). The
      mutation rate of EGFR over the age of 60 was significantly lower than that below 
      60 in surgical specimen, while it was not related to age in biopsy sample. The
      constituent ratio of pathology type was different in the two groups (chi2=8.04,
      P<0.05). Among 102 cases of lung adenocarcinoma in surgical specimen, the acinar 
      took up the highest proportion (54.9%), followed by the lepidic (23.53%) and the 
      papillary (17.65%). The solid adenocarcinoma accounted for the minimal percentage
      (3.9%). The mutation of 19 and 21 exon alone was most common. The mutation rate
      of 21 exon in the lepidic was higher than that in the acinar and papillary
      (P<0.05), but the mutation rate of 19 exon in the papillary was higher than that 
      in the lepidic (P<0.05). There was no significant difference of 19 and 21 exon in
      the acinar and papillary. Among 114 cases of lung adenocarcinoma in the biopsy
      specimen, the most percentage was the acinar (48.25%), the lepidic was secondly, 
      and the papillary, micropapillary and solid adenocarcinoma was the minimal. The
      exon mutation of 19 and 21 exon alone was most common, while no obvious
      difference of 19 and 21 exon was found in different pathology classifications
      (P>0.05). CONCLUSIONS: The mutation rate of EGFR of lung adenocarcinoma in
      surgical resected specimen and biopsy specimen was not found difference, which
      was related to sex, and the female was predominant. The mutation rate of surgical
      specimen was higher in the young, while that of biopsy specimen was not related
      to the age. Apparent difference of the pathology type proportion was found in the
      two groups. The mutation of 19 and 21 exon alone was most common. The mutation of
      EGFR in surgical specimens was related to pathology types. The percentage of the 
      lepidic adenocarcinoma was highest in the mutation of 21 exon alone. Among the
      mutation of 19 exon alone, the papillary was predominant. There was no obvious
      relationship between the mutation of 19 and 21 exon alone and pathology type in
      biopsy sample.
FAU - Kang, Lifei
AU  - Kang L
AD  - Department of Pathology, Peking University, Beijing 100191, China;Department of
      Pathology, Hebei Chest Hospital, Shijiazhuang 050041, China.
FAU - Zheng, Jie
AU  - Zheng J
AD  - Department of Pathology, Peking University, Beijing 100191, China.
FAU - Zhu, Xiang
AU  - Zhu X
AD  - Department of Pathology, Peking University, Beijing 100191, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - Adenocarcinoma of lung
SB  - IM
MH  - Adenocarcinoma/enzymology/*genetics/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Fine-Needle
MH  - Exons
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/enzymology/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Mutation Rate
MH  - Receptor, Epidermal Growth Factor/*genetics/metabolism
EDAT- 2017/06/24 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/24 06:00
AID - 10.3779/j.issn.1009-3419.2017.06.03 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):382-388. doi:
      10.3779/j.issn.1009-3419.2017.06.03.